Quince Therapeutics’ (QNCX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note issued to investors on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price target on the stock.

A number of other research firms have also recently issued reports on QNCX. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Maxim Group began coverage on shares of Quince Therapeutics in a research note on Thursday, November 7th. They set a “buy” rating and a $6.00 target price for the company. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Rodman & Renshaw began coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price target on the stock. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.50.

Quince Therapeutics Stock Performance

NASDAQ QNCX opened at $1.48 on Wednesday. The firm has a 50-day moving average of $1.79 and a 200-day moving average of $1.27. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a market cap of $65.12 million, a PE ratio of -1.19 and a beta of 0.61. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds have recently bought and sold shares of QNCX. Scharf Investments LLC bought a new position in Quince Therapeutics in the 4th quarter valued at about $170,000. Geode Capital Management LLC increased its holdings in Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock valued at $263,000 after buying an additional 66,170 shares during the period. Finally, Anfield Capital Management LLC bought a new position in Quince Therapeutics in the 4th quarter valued at about $50,000. 30.75% of the stock is owned by institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.